



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent  
Licensee of the Blue Cross and Blue Shield Association

## Medical Policy

# Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions

### Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

### Policy Number: 437

BCBSA Reference Number: 8.01.10

NCD/LCD: Local Coverage Determination (LCD): Proton Beam Therapy (L35075)

### Related Policies

- Clinical Exception and Notification Form for Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions, #[678](#)
- Intensity-Modulated Radiation Therapy (IMRT) of the Breast and Lung #[163](#)
- Intensity-Modulated Radiation Therapy (IMRT) of the Prostate #[090](#)
- Intensity-Modulated Radiation Therapy (IMRT): Abdomen and Pelvis #[165](#)
- Intensity-Modulated Radiation Therapy (IMRT): Cancer of the Head and Neck or Thyroid #[164](#)
- Stereotactic Radiosurgery and Stereotactic Body Radiotherapy #[277](#)

### Policy

#### Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Charged-particle irradiation with proton or helium ion beams may be considered **[MEDICALLY NECESSARY](#)** in the following clinical situations\*:

- Primary therapy for **melanoma of the uveal tract** (iris, choroid, or ciliary body), with no evidence of metastasis or extrascleral extension, and with tumors up to 24 mm in largest diameter and 14 mm in height;
- Postoperative therapy (with or without conventional high-energy x-rays) in patients who have undergone biopsy or partial resection of **chordoma or low-grade (I or II) chondrosarcoma of the basisphenoid region (skull-base chordoma or chondrosarcoma) or cervical spine**. Patients eligible for this treatment have residual localized tumor without evidence of metastasis.
- **Pediatric central nervous system tumors.**
- **Adult malignant and benign primary central nervous system tumors.**
- Primary or metastatic tumors of the **spine or tumors requiring craniospinal irradiation**, where the spinal cord tolerance may be exceeded with conventional treatment or where the spinal cord has previously been irradiated.

**\*Please note:** Clinical Exception and Notification form must be filled out and submitted prior to all proton beam therapy treatments.

Other applications of charged-particle irradiation with proton or helium ion beams are considered **INVESTIGATIONAL**. This includes, but is not limited to:

- Clinically localized prostate cancer
- Non-small-cell lung cancer (NSCLC) at any stage or for recurrence,
- Pediatric non-central nervous system tumors,
- Tumors of the head and neck (other than skull-based chordoma or chondrosarcoma).

### Clinical Exception and Notification Form\*

Providers must submit a request for an exception for a non-covered indication by completing the clinical exception and notification form. [Click here for the Proton Beam exception and notification form \(#678\)](#)

Providers must complete the Clinical Exception and Notification Form when requesting coverage:

- For medically necessary indications described in medical policy 437, Charged-Particle (Proton or Helium Ion) Radiation Therapy.
- For not medically necessary and investigational indications, described in medical policy 437, Charged-Particle (Proton or Helium Ion) Radiation Therapy.

The clinical exception/notification form is not required for Medicare Advantage members.

### Medicare HMO Blue<sup>SM</sup> and Medicare PPO Blue<sup>SM</sup> Members

Medical necessity criteria and coding guidance for **Medicare Advantage members living in Massachusetts** can be found through the link(s) below.

[Local Coverage Determinations \(LCDs\) for National Government Services, Inc.](#)

Local Coverage Determination (LCD): Proton Beam Therapy (L35075)

**Note:** To review the specific LCD, please remember to click “accept” on the CMS licensing agreement at the bottom of the CMS webpage.

For medical necessity criteria and coding guidance for **Medicare Advantage members living outside of Massachusetts**, please see the Centers for Medicare and Medicaid Services website at <https://www.cms.gov> for information regarding your specific jurisdiction.

### Prior Authorization Information

#### Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** if the procedure is performed inpatient.

#### Outpatient

- For services described in this policy, see below for situations where prior authorization might be required if the procedure is performed outpatient.

	Outpatient
<b>Commercial Managed Care (HMO and POS)</b>	Providers must complete the <a href="#">Clinical Exception and Notification Form</a> prior to service.
<b>Commercial PPO and Indemnity</b>	Providers must complete the <a href="#">Clinical Exception and Notification Form</a> prior to service.
<b>Medicare HMO Blue<sup>SM</sup></b>	Prior authorization is <b>not required</b> .
<b>Medicare PPO Blue<sup>SM</sup></b>	Prior authorization is <b>not required</b> .

## CPT Codes / HCPCS Codes / ICD Codes

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

*Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.*

*The following codes are included below for informational purposes only; this is not an all-inclusive list.*

**The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:**

### CPT Codes

CPT codes:	Code Description
77520	Proton treatment delivery; simple, without compensation
77522	Proton treatment delivery; simple with compensation
77523	Proton treatment delivery; intermediate
77525	Proton treatment delivery; complex

### Description

Charged-particle beams consisting of protons or helium ions are a type of particulate radiotherapy. They have several unique properties that distinguish them from conventional electromagnetic (ie, photon) radiotherapy, including minimal scatter as particulate beams pass through tissue, and deposition of ionizing energy at precise depths (ie, the Bragg peak). Thus, radiation exposure of surrounding normal tissues and critical structures is minimized. The theoretical advantages of protons and other charged-particle beams may improve outcomes when the following conditions apply:

- Conventional treatment modalities do not provide adequate local tumor control;
- Evidence shows that local tumor response depends on the dose of radiation delivered; and
- Delivery of adequate radiation doses to the tumor is limited by the proximity of vital radiosensitive tissues or structures.

### Summary

Charged-particle beams consisting of protons or helium ions are a type of particulate radiotherapy. Treatment with charged-particle radiotherapy is proposed for a large number of tumors that would benefit from the delivery of a high dose of radiation with limited scatter, minimizing the radiation dose to surrounding normal tissues and critical structures.

The following conclusions are based on a review of the evidence, including but not limited to, published evidence and clinical expert opinion.

For individuals who have uveal melanoma(s) who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes long-term studies, randomized controlled trials, and systematic reviews. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. Systematic reviews, including a 1996 TEC Assessment and a 2013 review of randomized and nonrandomized studies, concluded that the technology is at least as effective as alternative therapies for treating uveal melanomas and is better at preserving vision. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have a skull-based tumor(s) (ie, cervical chordoma, chondrosarcoma) who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes observational studies and systematic reviews. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. A 2007 systematic review found a 5-year overall survival rate of 81% with proton beam therapy (PBT) compared with 44% with surgery plus photon therapy. In 2018, a

meta-analysis found 5-year and 10-year overall survival rates for proton beam therapy of 78% and 60% compared with 46% and 21% for conventional radiotherapy. The published evidence supports a meaningful improvement in the net health outcome. Evidence reported through clinical input further supports that this use provides a clinically meaningful improvement in net health outcome and is consistent with generally accepted medical practice. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have pediatric central nervous system tumor(s) who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes case series, nonrandomized comparative studies, and systematic reviews. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. There are few comparative studies, and they tend to have small sample sizes. The available observational studies do not provide sufficient evidence on the efficacy of charged-particle therapy compared with other treatments (eg, intensity-modulated radiotherapy). Limitations of the published evidence preclude determining the effects of the technology on net health outcome. Evidence reported through clinical input supports that this use provides a clinically meaningful improvement in net health outcome and is consistent with generally accepted medical practice. This modality of treatment has the potential to reduce toxicity to organs at risk and may minimize the development of radiation-induced secondary malignancies, particularly in individuals with radiation-sensitizing genetic syndromes that are highly correlated with these tumor types. The evidence is sufficient to determine the effects of the technology on health outcomes.

For individuals who have pediatric non-central nervous system tumor(s) who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes dosimetric planning studies in a small number of patients. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. For this population, there is a lack of randomized and observational studies evaluating the efficacy and safety of this technology. Limitations of the published evidence preclude determining the effects of the technology on net health outcome. Evidence reported through clinical input supports that this use provides a clinically meaningful improvement in net health outcome and is consistent with generally accepted medical practice. This modality of treatment has the potential to reduce toxicity to organs at risk and may minimize the development of radiation-induced secondary malignancies. This intervention may be most suitable for patients treated with curative intent. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with central nervous system tumors, tumors of the spine, or with tumors requiring craniospinal irradiation, and where conventional or advanced photon-based radiotherapy may cause toxicity to organs at risk who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes a systematic review and retrospective studies. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. For this population, there is a lack of randomized and comparative studies evaluating safety and efficacy. Limitations of the published evidence preclude determining the effects of the technology on net health outcome. Evidence reported through clinical input supports that this use provides a clinically meaningful improvement in net health outcome and is consistent with generally accepted medical practice. This modality of treatment has the potential to reduce toxicity to healthy tissues, organs at risk, and may minimize the development of radiation-induced secondary malignancies. The evidence is sufficient to determine the effects of the technology on health outcomes.

For individuals who have localized prostate cancer who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes two randomized controlled trials and systematic reviews. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. A 2010 TEC Assessment addressed the use of PBT for prostate cancer and concluded that it had not been established whether PBT improves outcomes in any setting for clinically localized prostate cancer. The TEC Assessment included 2 randomized controlled trials, only one of which had a comparison group of patients that did not receive PBT. Limitations of the published evidence preclude determining the effects of the technology on net health outcome. Evidence reported through clinical input suggests a possible role for prostate cancer. However, support for its use is pending and a large, ongoing

phase III RCT comparing proton therapy to IMRT in prostate cancer may alter the conclusions of the TEC Assessment. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have non-small cell lung cancer who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes case series and systematic reviews. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. A 2010 TEC Assessment, which included 8 case series, concluded that the evidence was insufficient to permit conclusions about PBT for any stage of non-small-cell lung cancer. No subsequent randomized or nonrandomized comparative studies were identified that would alter the conclusions of the TEC Assessment. Limitations of the published evidence preclude determining the effects of the technology on net health outcome. Evidence reported through clinical input supports that this use provides a clinically meaningful improvement in net health outcome and is consistent with generally accepted medical practice. This modality of treatment has the potential to reduce toxicity to healthy tissues and organs at risk, with optimal outcomes observed for patients who are treated with curative intent. The evidence is sufficient to determine the effects of the technology on the health outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

## Policy History

Date	Action
3/2020	New medically necessary indications described for adult malignant and benign primary central nervous system tumors and primary or metastatic tumors of the spine or tumors requiring craniospinal irradiation based on Clinical Input and NCCN and ASTRO guidelines. Effective 3/1/2020.
9/2018	BCBSA National medical policy review. No changes to policy statements. New references added. Background and summary clarified.
9/2016	BCBSA National medical policy review. Title updated to indicate “for Neoplastic Conditions.” References added. 9/1/2016
8/2016	Updated to include Local Coverage Determination (LCD): Proton Beam Therapy (L35075). Effective 8/22/2016.
5/2016	BCBSA National medical policy review. The second policy statement was corrected to use the same “or helium ion” language as the first policy statement.
12/2015	BCBSA National medical policy review. Charged particle radiotherapy for clinically localized prostate cancer changed from “not medically necessary” to investigational. Title changed from “radiation therapy” to “radiotherapy.” Effective 12/1/2015.
9/2015	Local Coverage Determination (LCD): Proton Beam Therapy (L31617 added).
7/2014	BCBSA national medical policy review. New medical policy describing medically necessary, not medically necessary and investigational indications. Effective 7/1/2014.

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

## References

1. Spagnolo F, Caltabiano G, Queirolo P. Uveal melanoma. *Cancer Treat Rev.* Aug 2012;38(5):549-553. PMID 22270078.
2. Hawkins BS. Collaborative ocular melanoma study randomized trial of I-125 brachytherapy. *Clin Trials.* Oct 2011;8(5):661-673. PMID 22013172.
3. Pereira PR, Odashiro AN, Lim LA, et al. Current and emerging treatment options for uveal melanoma. *Clin Ophthalmol.* 2013;7:1669-1682. PMID 24003303.

4. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Charged particle (proton or helium ion) irradiation for uveal melanoma and for chordoma or chondrosarcoma of the skull base or cervical spine. TEC Assessments 1996;Volume 11:Tab 1.
5. Wang Z, Nabhan M, Schild SE, et al. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. *Int J Radiat Oncol Biol Phys*. May 1 2013;86(1):18-26. PMID 23040219.
6. Mishra KK, Quivey JM, Daftari IK, et al. Long-term Results of the UCSF-LBNL randomized trial: charged particle with helium ion versus iodine-125 plaque therapy for choroidal and ciliary body melanoma. *Int J Radiat Oncol Biol Phys*. Jun 1 2015;92(2):376-383. PMID 25841624.
7. Lin AJ, Rao YJ, Acharya S, et al. Patterns of care and outcomes of proton and eye plaque brachytherapy for uveal melanoma: Review of the National Cancer Database. *Brachytherapy*. Nov - Dec 2017;16(6):1225-1231. PMID 28966081.
8. Toutée A, Angi M, Dureau S et al. Long-Term Visual Outcomes for Small Uveal Melanoma Staged T1 Treated by Proton Beam Radiotherapy. *Cancers (Basel)*, 2019 Jul 28;11(8). PMID 31344948.
9. Lodge M, Pijls-Johannesma M, Stirk L, et al. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. *Radiother Oncol*. May 2007;83(2):110-122. PMID 17502116.
10. Zhou J, Yang B, Wang X et al. Comparison of the Effectiveness of Radiotherapy with Photons and Particles for Chordoma After Surgery: A Meta-Analysis. *World Neurosurg*, 2018 Jun 8;117:46-53. PMID 29879512.
11. Leroy R, Benahmed N, Hulstaert F, et al. Proton therapy in children: a systematic review of clinical effectiveness in 15 pediatric cancers. *Int J Radiat Oncol Biol Phys*. May 1 2016;95(1):267-278. PMID 27084646.
12. Huynh M, Marcu LG, Giles E et al. Current status of proton therapy outcome for paediatric cancers of the central nervous system - Analysis of the published literature. *Cancer Treat. Rev.*, 2018 Oct 17;70:272-288. PMID 30326423.
13. Bishop AJ, Greenfield B, Mahajan A, et al. Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. *Int J Radiat Oncol Biol Phys*. Oct 1 2014;90(2):354-361. PMID 25052561.
14. MacDonald SM, Trofimov A, Safai S, et al. Proton radiotherapy for pediatric central nervous system germ cell tumors: early clinical outcomes. *Int J Radiat Oncol Biol Phys*. Jan 1 2011;79(1):121-129. PMID 20452141.
15. Moeller BJ, Chintagumpala M, Philip JJ, et al. Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. *Radiat Oncol*. Jun 02 2011;6:58. PMID 21635776.
16. Hug EB, Muenter MW, Archambeau JO, et al. Conformal proton radiation therapy for pediatric low-grade astrocytomas. *Strahlenther Onkol*. Jan 2002;178(1):10-17. PMID 11977386.
17. Fuss M, Hug EB, Schaefer RA, et al. Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique. *Int J Radiat Oncol Biol Phys*. Dec 1 1999;45(5):1117-1126. PMID 10613303.
18. Kozak KR, Adams J, Krejcarek SJ, et al. A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas. *Int J Radiat Oncol Biol Phys*. May 1 2009;74(1):179-186. PMID 19019562.
19. Merchant TE. Proton beam therapy in pediatric oncology. *Cancer J*. Jul-Aug 2009;15(4):298-305. PMID 19672146.
20. Timmermann B. Proton beam therapy for childhood malignancies: status report. *Klin Padiatr*. May 2010;222(3):127-133. PMID 20514614.
21. Vogel J, Both S, Kirk M, et al. Proton therapy for pediatric head and neck malignancies. *Pediatr Blood Cancer*. Feb 2018;65(2). PMID 29058370.
22. Lesueur P, Calugaru V, Nauraye C et al. Proton therapy for treatment of intracranial benign tumors in adults: A systematic review. *Cancer Treat. Rev.*, 2018 Dec 12;72:56-64. PMID 30530009.
23. Jhaveri J, Cheng E, Tian S et al. Proton vs. Photon Radiation Therapy for Primary Gliomas: An Analysis of the National Cancer Data Base. *Front Oncol*, 2018 Dec 14;8:440. PMID 30547008.
24. Gunther JR, Rahman AR, Dong W et al. Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment. *Pract Radiat Oncol*, 2017 Jul 2;7(6). PMID 28666906.
25. Brown AP, Barney CL, Grosshans DR et al. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. *Int. J. Radiat. Oncol. Biol. Phys.*, 2013 Feb 26;86(2). PMID 23433794.

26. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Proton beam therapy for prostate cancer. TEC Assessments 2010;Volume 25:Tab 10.
27. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. *Int J Radiat Oncol Biol Phys.* Apr 30 1995;32(1):3-12. PMID 7721636.
28. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. *Jama.* Sep 14 2005;294(10):1233-1239. PMID 16160131.
29. Kim YJ, Cho KH, Pyo HR, et al. A phase II study of hypofractionated proton therapy for prostate cancer. *Acta Oncol.* Apr 2013;52(3):477-485. PMID 23398594.
30. Sun F, Oyesanmi O, Fontanarosa J, et al. Therapies for Clinically Localized Prostate Cancer: Update of a 2008 Systematic Review (Comparative Effectiveness Review No. 146). Rockville, MD: Agency for Healthcare Research and Quality; 2014.
31. Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. *Acta Oncol.* Aug 2004;43(4):316-381. PMID 15303499.
32. Kuban D, Pollack A, Huang E, et al. Hazards of dose escalation in prostate cancer radiotherapy. *Int J Radiat Oncol Biol Phys.* Dec 1 2003;57(5):1260-1268. PMID 14630260.
33. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Proton beam therapy for non- small-cell lung cancer. TEC Assessments. 2010;Volume 25:Tab 7.
34. Grutters JP, Kessels AG, Pijls-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. *Radiother Oncol.* Apr 2010;95(1):32-40. PMID 19733410.
35. Pijls-Johannesma M, Grutters JP, Verhaegen F, et al. Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review. *Oncologist.* Jan 2010;15(1):93-103. PMID 20067947.
36. Chang JY, Verma V, Li M, et al. Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non-small cell lung cancer: final results of a phase 2 study. *JAMA Oncol.* Aug 10 2017;3(8):e172032. PMID 28727865.
37. Ono T, Yabuuchi T, Nakamura T, et al. High dose hypofractionated proton beam therapy is a safe and feasible treatment for central lung cancer. *Radiol Oncol.* Sep 2017;51(3):324-330. PMID 28959169.
38. Patel SH, Wang Z, Wong WW, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. *Lancet Oncol.* Aug 2014;15(9):1027- 1038. PMID 24980873.
39. Blanchard P, Garden AS, Gunn GB et al. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. *Radiother Oncol.* 2016 Jun 28;120(1). PMID 27342249.
40. Zenda S, Kawashima M, Arahira S, et al. Late toxicity of proton beam therapy for patients with the nasal cavity, para-nasal sinuses, or involving the skull base malignancy: importance of long-term follow-up. *Int J Clin Oncol.* Jun 2015;20(3):447-454. PMID 25135461.
41. Mercado CE, Hartsell WF, Simone CB et al. Proton therapy for thymic malignancies: multi-institutional patterns-of-care and early clinical outcomes from the proton collaborative group and the university of Florida prospective registries. *Acta Oncol.* 2019 Feb 21;58(7). PMID 30784340.
42. Hoppe BS, Flampouri S, Zaiden R et al. Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study. *Int. J. Radiat. Oncol. Biol. Phys.,* 2014 Jun 15;89(5). PMID 24928256.
43. Hoppe BS, Tsai H, Larson G et al. Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry. *Acta Oncol.* 2016 Sep 1;55(11). PMID 27579554.
44. Verma V, Rwigema JM, Malyapa RS et al. Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation. *Radiother Oncol.* 2017 Sep 25;125(1). PMID 28941560.
45. Kammerer E, Guevelou JL, Chaikh A et al. Proton therapy for locally advanced breast cancer: A systematic review of the literature. *Cancer Treat. Rev.,* 2017 Dec 5;63:19-27. PMID 29197746.
46. Verma V, Shah C, Mehta MP. Clinical Outcomes and Toxicity of Proton Radiotherapy for Breast Cancer. *Clin. Breast Cancer.* 2016 Mar 21;16(3). PMID 26995159.
47. Xi M, Xu C, Liao Z et al. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. *Int. J. Radiat. Oncol. Biol. Phys.,* 2017 Dec 28;99(3). PMID 29280461.

48. Jethwa KR, Tryggestad EJ, Whitaker TJ et al. Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes. *Adv Radiat Oncol*, 2018 Sep 12;3(3). PMID 30202800.
49. Hitchcock KE, Nichols RC, Morris CG et al. Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer. *World J Gastrointest Surg*, 2017 May 16;9(4). PMID 28503258.
50. Ojerholm E, Kirk ML, Thompson RF et al. Pencil-beam scanning proton therapy for anal cancer: a dosimetric comparison with intensity-modulated radiotherapy. *Acta Oncol*, 2015 Mar 4;54(8). PMID 25734796.
51. Chang JY, Jabbour SK, De Ruyscher D, et al. Consensus statement on proton therapy in early-stage and locally advanced non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. May 1 2016;95(1):505-516. PMID 27084663.
52. Nguyen PL, Aizer A, Assimos DG, et al. ACR Appropriateness Criteria(R) Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer. *Am J Clin Oncol*. Jun 2014;37(3):278-288. PMID 25180754.
53. National Comprehensive Cancer Network (NCCN). NCCN Radiation Therapy Compendium. <https://www.nccn.org/professionals/radiation/content/>. Accessed September 2, 2019.
54. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf). Accessed September 2, 2019.
55. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 7.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). Accessed September 2, 2019.
56. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Head and neck cancers. Version 2.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/head-and-neck.pdf](https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf). Accessed September 2, 2019.
57. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/cns.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf). Accessed September 2, 2019.
58. American Society for Radiation Oncology (ASTRO). ASTRO Model Policies: Proton Beam Therapy (PBT). 2017; [https://www.astro.org/uploadedFiles/\\_MAIN\\_SITE/Daily\\_Practice/Reimbursement/Model\\_Policies/Content\\_Pieces/ASTROPBTModelPolicy.pdf](https://www.astro.org/uploadedFiles/_MAIN_SITE/Daily_Practice/Reimbursement/Model_Policies/Content_Pieces/ASTROPBTModelPolicy.pdf). Accessed September 2, 2019.